Chemed Corp: Form 10-Q for the period ended Sep 30, 2017
Filed with the SEC on Oct 27, 2017 and accepted by EDGAR at Oct 27, 2017, 11:17 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2017-07-01 to 2017-09-30 | $288.0m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2017-01-01 to 2017-09-30 | $859.0m | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months2017-07-01 to 2017-09-30 | $66.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2017-01-01 to 2017-09-30 | $205.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2017-07-01 to 2017-09-30 | $54.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2017-01-01 to 2017-09-30 | $56.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2017-07-01 to 2017-09-30 | $1.0m | us-gaap:InterestExpense |
| Interest expense | 9 months2017-01-01 to 2017-09-30 | $3.2m | us-gaap:InterestExpense |
| Income tax | 3 months2017-07-01 to 2017-09-30 | $18.8m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2017-01-01 to 2017-09-30 | $15.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-07-01 to 2017-09-30 | $35.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months2017-01-01 to 2017-09-30 | $43.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-07-01 to 2017-09-30 | $2.13 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2017-01-01 to 2017-09-30 | $2.60 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-07-01 to 2017-09-30 | $2.22 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2017-01-01 to 2017-09-30 | $2.72 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2017-07-01 to 2017-09-30 | 16,676,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2017-01-01 to 2017-09-30 | 16,763,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 9 months2017-01-01 to 2017-09-30 | $50.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2017-01-01 to 2017-09-30 | $12.9m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months2017-01-01 to 2017-09-30 | $94.6m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2017-09-30 | $18.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-09-30 | $135.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-09-30 | $895.5m | us-gaap:Assets |
| Current liabilities | At period end2017-09-30 | $269.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-09-30 | $417.8m | us-gaap:Liabilities |
| Long-term debt | At period end2017-09-30 | $72.5m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2017-09-30 | $10.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2017-09-30 | $477.7m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2017-09-30 | 15,966,003 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001157523-17-002853. Last ingested by Listed: Nov 5, 2026, 15:55 ET. Listed shows no prices and gives no investment advice.